<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183115</url>
  </required_header>
  <id_info>
    <org_study_id>ED102807</org_study_id>
    <secondary_id>MOST105-2314-B-650-005</secondary_id>
    <nct_id>NCT03183115</nct_id>
  </id_info>
  <brief_title>RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection</brief_title>
  <official_title>Preemptive Radiofrequency Ablation for Esophageal Speckled Lugol Background Mucosa to Prevent Metachronous Neoplastic Recurrence After Complete Endoscopic Submucosal Dissection ~A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>E-DA Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esophageal cancer is a highly lethal disease, and its incidence is still increasing in the
      world. Recent advances in image-enhanced techniques such as Lugol chromoendoscopy and narrow
      band imaging, the number of patients with early esophageal squamous cell neoplasias (ESCNs)
      detected has markedly increased. Endoscopic submucosal dissection (ESD) enables en bloc
      resection of the neoplasia, and the resected specimen allows for a pathological assessment to
      evaluate the curability. However, the patients who received complete ESD for early ESCNs
      frequently developed metachronous recurrence. The cumulative metachronous recurrence rate at
      5 years was 50%, and the mean annual incidence of newly diagnosed metachronous tumors was
      10%. Among them, those with &quot;speckled&quot; lugol staining pattern over the esophageal background
      mucosa have the highest risk and should be seen as a precancerous lesion of ESCCs. This issue
      is gaining attention in the era of endoscopic treatment, but currently there was no
      appropriate strategy to prevent the tumor recurrence in these high-risk subjects.

      Endoscopic radiofrequency ablation (RFA) is a rapidly evolving therapeutic modality, and
      recent studies have shown its efficacy and safety for eradicating for flat type early ESCNs.
      To search a best strategy for the prevention of ESCNs, the investigators thus propose a
      hypothesis that the preemptive RFA for esophageal &quot;speckled&quot; lugol background mucosa may
      prevent the metachronous neoplastic recurrence after complete endoscopic resection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor recurrence</measure>
    <time_frame>From date of randomization until the date of first documented tumor recurrence, assessed up to 100 months</time_frame>
    <description>Metachronous tumor recurrence is defined as a tumor (high-grade dysplasia or squamous cell carcinoma) recurring at a new site after more than 6 months of complete remission status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse events</measure>
    <time_frame>From date of intervention until the date of first documented adverse events, assessed up to 12months</time_frame>
    <description>including perforation, dysphagia, stenosis, defined as the failure of a standard endoscope (9.8 mm in diameter) to pass through the stenosis, or others resulting in the patients intolerable and discontinued intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Esophageal Squamous Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>RFA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balloon type RFA (12J/cm2, 1 application) will be applied for the entire speckled esophageal mucosa at the 3 months after complete ESD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention; surveillance endoscopy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>HALO360 System (Covidien GI Solutions, Sunnyvale, California, USA), which has been approved by the US Food and Drug Administration (FDA) and is approved for use in Europe (CE mark) and Taiwan (Ministry of Health and Welfare).</description>
    <arm_group_label>RFA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopy</intervention_name>
    <description>The participants will receive meticulous endoscopic examination with Lugol chromoendoscopy and Narrow-band imaging</description>
    <arm_group_label>RFA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lugol's Solution (1.5%)</intervention_name>
    <description>Before the RFA intervention, the participants will received Lugol staining over the esophagus</description>
    <arm_group_label>RFA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with early stage ESCNs (squamous high grade dysplasia, carcinoma in situ, or
             T1N0M0 SCC) who were treated by endoscopic submucosal dissection.

          -  Lugol staining showed &quot;speckled&quot; (&gt;10 small lugol-unstained lesions) pattern of
             background mucosa.

        Exclusion Criteria:

          -  Having a history of incomplete endoscopic treatment, or complications during/after
             treatment (perforation, stricture).

          -  Having history of systemic chemotherapy or radiation therapy for esophagus or post
             esophagectomy.

          -  Life expectancy &lt;2 yr.

          -  Decompensated cirrhosis (Child score B, C).

          -  Having large esophageal varices.

          -  Poor performance status (ECOG&gt;2).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wen-Lun Wang, Ph.D</last_name>
    <phone>886-7-6150011</phone>
    <phone_ext>251346</phone_ext>
    <email>warrengodr@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ching-Tai Lee, M.D.</last_name>
    <phone>886-7-6150011</phone>
    <phone_ext>251205</phone_ext>
    <email>fattoo@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>EDA Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Lun Wang, Ph.D</last_name>
      <phone>886-7-6150011</phone>
      <phone_ext>251346</phone_ext>
      <email>warrengodr@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Lee CT, Chang CY, Lee YC, Tai CM, Wang WL, Tseng PH, Hwang JC, Hwang TZ, Wang CC, Lin JT. Narrow-band imaging with magnifying endoscopy for the screening of esophageal cancer in patients with primary head and neck cancers. Endoscopy. 2010 Aug;42(8):613-9. doi: 10.1055/s-0030-1255514. Epub 2010 Jul 28.</citation>
    <PMID>20669074</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee CT, Chang CY, Tai CM, Wang WL, Tseng CH, Hwang JC, Lin JT. Endoscopic submucosal dissection for early esophageal neoplasia: a single center experience in South Taiwan. J Formos Med Assoc. 2012 Mar;111(3):132-9. doi: 10.1016/j.jfma.2010.12.002. Epub 2012 Feb 8.</citation>
    <PMID>22423666</PMID>
  </results_reference>
  <results_reference>
    <citation>Shimizu Y, Tukagoshi H, Fujita M, Hosokawa M, Kato M, Asaka M. Metachronous squamous cell carcinoma of the esophagus arising after endoscopic mucosal resection. Gastrointest Endosc. 2001 Aug;54(2):190-4.</citation>
    <PMID>11474389</PMID>
  </results_reference>
  <results_reference>
    <citation>Urabe Y, Hiyama T, Tanaka S, Oka S, Yoshihara M, Arihiro K, Chayama K. Metachronous multiple esophageal squamous cell carcinomas and Lugol-voiding lesions after endoscopic mucosal resection. Endoscopy. 2009 Apr;41(4):304-9. doi: 10.1055/s-0029-1214477. Epub 2009 Apr 1.</citation>
    <PMID>19340732</PMID>
  </results_reference>
  <results_reference>
    <citation>Muto M, Hironaka S, Nakane M, Boku N, Ohtsu A, Yoshida S. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc. 2002 Oct;56(4):517-21.</citation>
    <PMID>12297767</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthusamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009 May 28;360(22):2277-88. doi: 10.1056/NEJMoa0808145.</citation>
    <PMID>19474425</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, Sharma VK, Eisen GM, Fennerty MB, Hunter JG, Bronner MP, Goldblum JR, Bennett AE, Mashimo H, Rothstein RI, Gordon SR, Edmundowicz SA, Madanick RD, Peery AF, Muthusamy VR, Chang KJ, Kimmey MB, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Dumot JA, Falk GW, Galanko JA, Jobe BA, Hawes RH, Hoffman BJ, Sharma P, Chak A, Lightdale CJ. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology. 2011 Aug;141(2):460-8. doi: 10.1053/j.gastro.2011.04.061. Epub 2011 May 6.</citation>
    <PMID>21679712</PMID>
  </results_reference>
  <results_reference>
    <citation>Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, Fullarton G, Di Pietro M, Ravi N, Visser M, Offerhaus GJ, Seldenrijk CA, Meijer SL, ten Kate FJ, Tijssen JG, Bergman JJ. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014 Mar 26;311(12):1209-17. doi: 10.1001/jama.2014.2511.</citation>
    <PMID>24668102</PMID>
  </results_reference>
  <results_reference>
    <citation>Bergman JJ, Zhang YM, He S, Weusten B, Xue L, Fleischer DE, Lu N, Dawsey SM, Wang GQ. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. Gastrointest Endosc. 2011 Dec;74(6):1181-90. doi: 10.1016/j.gie.2011.05.024. Epub 2011 Aug 15.</citation>
    <PMID>21839994</PMID>
  </results_reference>
  <results_reference>
    <citation>van Vilsteren FG, Alvarez Herrero L, Pouw RE, ten Kate FJ, Visser M, Seldenrijk CA, van Berge Henegouwen MI, Weusten BL, Bergman JJ. Radiofrequency ablation for the endoscopic eradication of esophageal squamous high grade intraepithelial neoplasia and mucosal squamous cell carcinoma. Endoscopy. 2011 Apr;43(4):282-90. doi: 10.1055/s-0030-1256309. Epub 2011 Mar 31.</citation>
    <PMID>21455869</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang WL, Chang IW, Chang CY, Lin JT, Mo LR, Wang HP, Lee CT. Circumferential balloon-based radiofrequency ablation for ultralong and extensive flat esophageal squamous neoplasia. Gastrointest Endosc. 2014 Dec;80(6):1185-9. doi: 10.1016/j.gie.2014.07.025. Epub 2014 Sep 23.</citation>
    <PMID>25257127</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang WL, Chang IW, Chen CC, Chang CY, Mo LR, Lin JT, Wang HP, Lee CT. Radiofrequency Ablation Versus Endoscopic Submucosal Dissection in Treating Large Early Esophageal Squamous Cell Neoplasia. Medicine (Baltimore). 2015 Dec;94(49):e2240. doi: 10.1097/MD.0000000000002240.</citation>
    <PMID>26656367</PMID>
  </results_reference>
  <results_reference>
    <citation>He S, Bergman J, Zhang Y, Weusten B, Xue L, Qin X, Dou L, Liu Y, Fleischer D, Lu N, Dawsey SM, Wang GQ. Endoscopic radiofrequency ablation for early esophageal squamous cell neoplasia: report of safety and effectiveness from a large prospective trial. Endoscopy. 2015 May;47(5):398-408. doi: 10.1055/s-0034-1391285. Epub 2015 Feb 10.</citation>
    <PMID>25668428</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early esophageal squamous cell neoplasm</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Endoscopic submucosal dissection</keyword>
  <keyword>Esophageal cancer</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Field cancerization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lugol's solution</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The initial outcome and the data of adverse events will be shared with other researchers, by mail, when they are available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

